Abstract: Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the circulatory level of a hormone in a mammalian host, such as diseased states characterized by abnormally depressed circulatory levels of the hormone.
Type:
Grant
Filed:
September 25, 2001
Date of Patent:
September 16, 2003
Assignee:
The Regents of the University of California
Abstract: Novel medicinal compositions aiming at delivering a medicine to a specific site of the large intestine; and preparations for intestinal administration with the use of the same. Namely, medicinal compositions, whereby a medicine can be delivered to a specific site of the large intestine, characterized by containing a P-glycoprotein modifier; and preparations for intestinal administration with the use of the same.
Abstract: A blood collection system and method are disclosed in which taurolidine, a neutralizing agent for pathogens is added to the blood collected in standard blood bags. The taurolidine agent may be prepositioned in the collection bag prior to the collection of blood or alternatively the taurolidine may be added after the collection of blood has been completed.
Abstract: In accordance with the present invention, there is provided a class of compounds which are capable of modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-&ggr;). The identification of such compounds makes it possible to intervene in PPAR-&ggr; mediated pathways.
Type:
Grant
Filed:
May 8, 2002
Date of Patent:
August 12, 2003
Assignee:
The Salk Insitute for Biological Studies
Abstract: Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.
Type:
Application
Filed:
December 27, 2002
Publication date:
July 31, 2003
Applicant:
Myriad Genetics, Incorporated
Inventors:
Fabiana Filigheddu, Julia Reid, Susanne Wagner
Abstract: The present invention relates to a use of SUR1/Kir6.2 selective potassium channel openers for the preparation of a pharmaceutical composition for the prevention or the treatment of diabetes, and for the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome (PCOS) as well as a pharmaceutical composition for use in the prevention or the treatment of diabetes, and in the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome.
Abstract: The present invention relates to a use of SUR1/Kir6.2 selective potassium channel openers for the preparation of a pharmaceutical composition for the prevention or the treatment of diabetes in women with prior Gestational Diabetes Mellitus (GDM) as well as a pharmaceutical composition for use in the treatment of diabetes in women with prior GDM.
Abstract: New methods are provided for treating against apoptotic cell death, including apoptotic cardiac and neuronal cells. Therapies of the invention include administration of a mitochondrial oxidizer compound to a subject in need thereof, such as a subject suffering from or susceptible to stroke, heart attack, brain or spinal cord trauma, or chronic conditions that can resulting apoptotic cell death such as a neurodegenerative disease.
Type:
Grant
Filed:
October 15, 2001
Date of Patent:
February 18, 2003
Assignee:
The Johns Hopkins University
Inventors:
Eduardo Marban, Brian O'Rourke, Masaharu Akao
Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:
(A) at least one taurinamide derivative, and
(B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
Abstract: The present invention is concerned with solid oral dosage forms of comprising
a) an active agent selected from valsartan and optionally HCTZ , and
b) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
November 26, 2002
Assignee:
Novartis AG
Inventors:
Robert Frank Wagner, Yoshimitsu Katakuse, Takashi Taike, Fujiki Yamato, Manfred Kohlmeyer
Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
Type:
Application
Filed:
August 2, 2001
Publication date:
November 7, 2002
Inventors:
Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
Abstract: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
Type:
Application
Filed:
September 14, 2001
Publication date:
October 10, 2002
Inventors:
Yuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Stephen Jones, Mike McLane
Abstract: The present invention relates to a novel processes for preparing pharmaceutically active fused 1,2,4-thiadiazine derivatives of general formula (I) as defined in the description and intermediates therefore.
Abstract: The present invention involves certain 8-ureido and 8-thioureido, 1,2-benzothiazines, 1,2,4-benzothioxazines and 1,2,4-benzothiodiazines useful in the treatment of disease states mediated by the chemokine, Interleukin-8.
Abstract: The present invention relates to methods of treating SD associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor.
Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:
(A) at least one taurinamide derivative, and
(B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
Abstract: New methods are provided for treating against apoptotic cell death, including apoptotic cardiac and neuronal cells. Therapies of the invention include administration of a mitochondrial oxidizer compound to a subject in need thereof, such as a subject suffering from or susceptible to stroke, heart attack, brain or spinal cord trauma, or chronic conditions that can resulting apoptotic cell death such as a neurodegenerative disease.
Type:
Application
Filed:
October 15, 2001
Publication date:
July 11, 2002
Applicant:
Johns Hopkins University
Inventors:
Eduardo Marban, Brian O'Rourke, Masaharu Akao
Abstract: In accordance with the present invention, there is provided a class of compounds which are capable of modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-&ggr;). The identification of such compounds makes it possible to intervene in PPAR-&ggr; mediated pathways.
Type:
Grant
Filed:
February 16, 2001
Date of Patent:
July 2, 2002
Assignee:
The Salk Institute for Biological Studies
Abstract: The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neurophsyciatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed.
Abstract: The present invention relates to the use of potassium channel agonists for reducing or lowering the consumption of fat food. The present invention also embraces the use of the compounds of general formulas (I) and (Ia) in reducing or lowering the intake of fat food and methods of using the compounds and their pharmaceutical compositions.
Abstract: The present invention relates to the use of potassium channel agonists for treating cancer, more particular the treatment and/or prevention of breast cancer and endometrial cancer. The present invention also embraces the use of the compounds of general formulas (I) and (Ia) in treating cancer and methods of using the compounds and their pharmaceutical compositions.
Abstract: Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the circulatory level of a hormone in a mammalian host, such as diseased states characterized by abnormally depressed circulatory levels of the hormone.
Type:
Grant
Filed:
May 9, 1997
Date of Patent:
December 11, 2001
Assignee:
The Regents of the University of California
Abstract: This invention relates to cyclic combination therapies utilizing, in combination with a progestin, an estrogen, or both, progesterone receptor antagonists of the general structure:
wherein the substituents are as defined herein, or pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
April 19, 2000
Date of Patent:
November 20, 2001
Assignees:
American Home Products Corporation, Ligand Pharmaceuticals, Inc.
Inventors:
Gary S. Grubb, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley, Mark A. Collins, Valerie A. Mackner, Jay E. Wrobel
Abstract: The present invention is generally directed to potassium adenosine triphosphate (“KATP”) channel opening compositions. The present invention also relates to the use of KATP channel openers in therapeutic applications. The KATP channel opening compositions of the present invention include diazoxide (7-chloro-3-methyl-2H-1,2,4-benzo-thiadiazine 1,1-dioxide) and aprikalim. According to the present invention, diazoxide and aprikalim can be used independently, or in combination. The present also relates to therapeutic methods for protecting neuronal function utilizing KATP channel openers. Methods of the present invention may be advantageous for protecting neuronal function, prior to medical procedures, after stroke-like events or other events associated with reductions in blood flow, and/or for preserving tissues or organs against cellular injury and death during removal, storage, transplantation or reattachment.
Abstract: The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
Type:
Grant
Filed:
May 7, 1999
Date of Patent:
September 25, 2001
Assignee:
Novartis AG
Inventors:
Robert Frank Wagner, Yoshimitsu Katakuse, Takashi Taike, Fujiki Yamato, Manfred Kohlmeyer
Abstract: This invention relates to synergistic compositions of oxathiazines and benzothiophene-2-carboxamide-S,S-dioxides for use as fungicidal preservatives in the protection of materials, such as protection of wood, wood products, biodegradable materials and coatings.
Type:
Grant
Filed:
April 10, 2000
Date of Patent:
June 5, 2001
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Ludo Antoinnette De Witte, Alex Raymond Albert Valcke, Mark Arthur Josepha Van der Flaas, Willy Modest Louisa Willems
Abstract: 1,2,4-Benzothiadiazine derivatives represented by formula
wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, composition thereof and methods for preparing the compounds are described.
The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.
Type:
Grant
Filed:
June 17, 1997
Date of Patent:
June 5, 2001
Assignee:
Novo Nordisk AIS
Inventors:
Bernard Pirotte, Philippe Lebrun, Pascal De Tullio, Fabian Somers, Jacques Delarge, John Bondo Hansen, Flemming Elmelund Nielsen, Holger Claus Hansen, John Patrick Mogensen, Tina Møller-Tagmose
Abstract: In accordance with the present invention, there is provided a class of compounds which are capable of modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-&ggr;). The identification of such compounds makes it possible to intervene in PPAR-&ggr; mediated pathways.
Type:
Grant
Filed:
February 22, 1999
Date of Patent:
April 10, 2001
Assignee:
The Salk Institute for Biological Studies
Abstract: The present invention discloses a treatment for syndrome-X, and resulting complications, that include hyperlipidemia, hypertension, central obesity, hyperinsulinemia and impaired glucose intolerance. Diabetic complications include excess proinsulin levels.